Bristol-Myers Squibb Company (BMY) Stock Analysis
Healthcare · Drug Manufacturers - General · NYSE
Bristol-Myers Squibb Company (BMY) posted $48.19B in revenue for fiscal 2025 (down 0.2% year over year), at a 14.6% net margin, and has compounded revenue about 2.5%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Bristol-Myers Squibb Company
Bristol-Myers Squibb Company has grown revenue from $19.43B to $48.19B over the last 10 fiscal years, compounding about 2.5% a year. The most recent year was down 0.2%, so growth has cooled from its longer-run pace.
Net margin sits at 14.6%, up 33.1 points year over year on a 71.1% gross margin. It carries about $47.09B of total debt.
At today's valuation the market is pricing in roughly -1.3% annual free-cash-flow growth — versus the -0.7% it actually delivered over the last five years, broadly in line with what it has delivered.
Synthesised from Bristol-Myers Squibb Company's SEC filings — descriptive, not advice. Ask the analyst your own question →
Bristol-Myers Squibb Company revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.43B | $20.78B | $22.56B | $26.14B | $42.52B | $46.38B | $46.16B | $45.01B | $48.30B | $48.19B |
| Gross profit | $14.48B | $14.68B | $16.09B | $18.07B | $30.75B | $36.45B | $36.02B | $34.31B | $34.33B | $34.26B |
| Net income | $4.46B | $1.01B | $4.92B | $3.44B | $-9.02B | $6.99B | $6.33B | $8.03B | $-8.95B | $7.05B |
| Net margin | 22.9% | 4.8% | 21.8% | 13.2% | -21.2% | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% |
Source: Bristol-Myers Squibb Company SEC filings (10-K). 19 years of history available in the interactive view.
Bristol-Myers Squibb Company: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
What growth is priced into BMY stock?
At today's market cap of $133.41B, Bristol-Myers Squibb Company is priced for free-cash-flow growth of about -1.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $12.85B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.7%/yr over the last five fiscal years and revenue 2.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Bristol-Myers Squibb Company financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BMY in your portfolio →
Bristol-Myers Squibb Company financial history by metric
Compare Bristol-Myers Squibb Company with peers
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company — frequently asked questions
What is Bristol-Myers Squibb Company's revenue?
Bristol-Myers Squibb Company (BMY) reported revenue of $48.19B for fiscal year 2025, down 0.2% from the prior year, according to its SEC filings.
Is Bristol-Myers Squibb Company profitable?
Yes. BMY earned net income of $7.05B in fiscal 2025, a net margin of 14.6%.
What is BMY's P/E ratio?
Bristol-Myers Squibb Company trades at a price-to-earnings ratio of about 14.4 based on the latest data in our nightly-refreshed cache.
How fast is Bristol-Myers Squibb Company growing?
BMY's revenue grew at roughly 2.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Bristol-Myers Squibb Company have?
As of fiscal year 2025, BMY carried roughly $47.09B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Bristol-Myers Squibb Company's gross margin?
BMY's gross margin was 71.1% in fiscal 2025 — gross profit of $34.26B on revenue of $48.19B.
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company (BMY) has a market capitalization of about $133.41B, based on the latest data in our nightly-refreshed cache.
When does Bristol-Myers Squibb Company's fiscal year end?
BMY's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BMY stock?
At today's market cap of $133.41B, Bristol-Myers Squibb Company is priced for free-cash-flow growth of about -1.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $12.85B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.7%/yr over the last five fiscal years and revenue 2.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Bristol-Myers Squibb Company's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.